安非他酮治疗抑郁障碍的疗效和安全性

目的：评价安非他酮治疗抑郁症的疗效和安全性。方法将60例符合CCMD-3诊断标准的抑郁症患者随机分为安非他酮组和丙米嗪组各30例，分别治疗6周。采用汉密尔顿抑郁量表（ HAMD）评定疗效，采用副反应量表（ TESS）评定药物的不良反应。结果两组治疗后HAMD评分均较治疗前有显著降低（ P﹤0.05），治疗1、2、4、6周末两组间HAMD评分均无显著差异（ P﹥0.05）。治疗第4、6周末，安非他酮组TESS评分低于丙米嗪组，差异有显著性（P﹤0.05）。结论安非他酮治疗抑郁症有效，且不良反应发生率低于丙米嗪。

Efficacy and Safety of Bupropion in the treatment of depression

Objective：To evaluate the efficacy and safety of Bupropion in the treatment of depression. Methods 60 patients who met CCMD-3 were assigned randomly into the Bupropion group or the Imipramine group. The Bupropion group was treated with Burpropion,while the Imipramine group was treated with Imipramine for 6 weeks. Effects and side effects were evalued seperately with HAMD and TESS before and after the treatment. Results：The scores of HAMD decreased significant-ly in both group after the completion of treatment（P﹤0. 05）,while in each same period,the scores shew no significant difference between the two group（P﹥0. 05）. The scores of TESS in Bupropion group became significantly lower than in the Imipramine at the end of 4 and 6 week（P﹤0. 05）. Conclusion：Bupropion can improve the therapeutic effect significantly and less side effects than Imipramine.